Cytokinetics

We are a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors. These treatments target debilitating diseases where muscle performance is compromised, such as heart failure, Amyotrophic Lateral Sclerosis (ALS), and hypertrophic cardiomyopathy (HCM).

For over 25 years, we have specialized in muscle biology, creating small molecule drug candidates that impact muscle function. We started operations in South San Francisco in 1998 and went public in 2004. In 2008, we began focusing our research on muscle biology. Significant clinical progress includes starting a Phase 1 study for a cardiac myosin inhibitor in 2018, announcing results from the pivotal Phase 3 SEQUOIA-HCM clinical trial in 2023, and results from the Phase 3 MAPLE-HCM clinical trial in 2025. In 2024, the FDA accepted our New Drug Application for a potential cardiac myosin inhibitor, and in 2025, we received FDA approval for our first medicine.

We have published over 115 papers, conducted more than 100 clinical trials, and hold hundreds of patents. Our global headquarters is in South San Francisco, CA, with offices in Radnor, PA, Zug, Switzerland, and Dublin, Ireland, plus other European affiliates.

Our vision is to be a leading muscle-focused biopharmaceutical company that improves patients’ lives through global access to innovative medicines. Our mission is to develop new medicines that can improve outcomes for people living with debilitating cardiovascular and neuromuscular muscle dysfunction.

Our core values guide our culture: Patients are our North Star, Science is in our Soul, We > Me, and Make it Happen. We are committed to putting patients first, operating with a strong moral compass, and building a diverse and inclusive culture.

We have between 501 and 1000 employees. We foster an empowered culture where employees are encouraged to pursue professional and personal goals, promoting individual expression and exploration. We are a values-driven, high-integrity, diverse, and inclusive workplace, working to increase representation for women and underrepresented groups in leadership.

We have been recognized as a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022, and part of Fortune’s Best Workplaces in the Bay Area and Fortune’s Best Workplaces in BioPharma in 2022. We offer early career opportunities through an Internship Program and a Postdoc Program.

We offer competitive benefits packages.

Our health benefits include medical, dental, vision, an employee assistance program, life insurance, short- and long-term disability insurance, and business travel accident insurance.

Financial benefits include a 401(k) plan, an employee stock purchase plan, healthcare and dependent care reimbursement accounts, a health savings account, pet insurance, a transportation reimbursement account, credit union access, and financial planning resources.

Time off benefits include 20 days of paid time off per year, with additional days for employees with over five years of tenure. We also offer paid holidays, a winter shutdown, 8 weeks of paid new parental/baby bonding leave, and up to 12 weeks of paid medical leave.

Depending on location, onsite services may include a subsidized café, a gym with fitness classes, a juice bar, and wellness rooms. Additional benefits include a hybrid work schedule, dedicated time off for volunteer activities, employee resource groups, educational assistance, an employee referral program, adoption assistance, annual flu shots, company sports teams, and team building events.